The clinical aspects of autoantibodies

John D. Paulin, Neil McHugh

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Disease classification in systemic sclerosis (SSc) is based primarily on the extent of skin involvement due to the recognition of its capacity to predict organ-specific manifestations. However, as shall be discussed in this chapter, antibody specificity, despite certain limitations, may prove of greater importance in predicting disease course and prognosis [1]. Circulating autoantibodies are attractive as biomarkers in SSc owing to their high specificity, the mutual exclusivity of the major SScautoantibody subtypes, their persistence for the duration of illness and most importantly, the characteristic constellation of clinical features associated with individual autoantibody groups [2, 3]. It is important to note, however, that the major clinical associations with SSc specific autoantibody reactivities, whilst of major prognostic value, are not absolute and organspecific manifestations can occur in the presence of any autoantibody reactivity [4].

LanguageEnglish
Title of host publicationScleroderma
Subtitle of host publicationFrom Pathogenesis to Comprehensive Management
EditorsJohn Varga, Christopher P. Denton, Fredrick M. Wigley
Place of PublicationNew York
PublisherSpringer
Pages209-225
Number of pages17
ISBN (Electronic)9781441957740
ISBN (Print)9781441957733
DOIs
StatusPublished - 1 Jan 2012

Fingerprint

Autoantibodies
Systemic Scleroderma
Antibody Specificity
Biomarkers
Skin

Keywords

  • ANA
  • Anticentromere
  • Autoantibody types
  • Clinical aspects of autoantibodies
  • Methods of autoantibody detection
  • RNA polymerase III
  • Scl-70

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Paulin, J. D., & McHugh, N. (2012). The clinical aspects of autoantibodies. In J. Varga, C. P. Denton, & F. M. Wigley (Eds.), Scleroderma: From Pathogenesis to Comprehensive Management (pp. 209-225). New York: Springer. https://doi.org/10.1007/978-1-4419-5774-0_18

The clinical aspects of autoantibodies. / Paulin, John D.; McHugh, Neil.

Scleroderma: From Pathogenesis to Comprehensive Management. ed. / John Varga; Christopher P. Denton; Fredrick M. Wigley. New York : Springer, 2012. p. 209-225.

Research output: Chapter in Book/Report/Conference proceedingChapter

Paulin, JD & McHugh, N 2012, The clinical aspects of autoantibodies. in J Varga, CP Denton & FM Wigley (eds), Scleroderma: From Pathogenesis to Comprehensive Management. Springer, New York, pp. 209-225. https://doi.org/10.1007/978-1-4419-5774-0_18
Paulin JD, McHugh N. The clinical aspects of autoantibodies. In Varga J, Denton CP, Wigley FM, editors, Scleroderma: From Pathogenesis to Comprehensive Management. New York: Springer. 2012. p. 209-225 https://doi.org/10.1007/978-1-4419-5774-0_18
Paulin, John D. ; McHugh, Neil. / The clinical aspects of autoantibodies. Scleroderma: From Pathogenesis to Comprehensive Management. editor / John Varga ; Christopher P. Denton ; Fredrick M. Wigley. New York : Springer, 2012. pp. 209-225
@inbook{e8cf91154193411da768e3d69b94c296,
title = "The clinical aspects of autoantibodies",
abstract = "Disease classification in systemic sclerosis (SSc) is based primarily on the extent of skin involvement due to the recognition of its capacity to predict organ-specific manifestations. However, as shall be discussed in this chapter, antibody specificity, despite certain limitations, may prove of greater importance in predicting disease course and prognosis [1]. Circulating autoantibodies are attractive as biomarkers in SSc owing to their high specificity, the mutual exclusivity of the major SScautoantibody subtypes, their persistence for the duration of illness and most importantly, the characteristic constellation of clinical features associated with individual autoantibody groups [2, 3]. It is important to note, however, that the major clinical associations with SSc specific autoantibody reactivities, whilst of major prognostic value, are not absolute and organspecific manifestations can occur in the presence of any autoantibody reactivity [4].",
keywords = "ANA, Anticentromere, Autoantibody types, Clinical aspects of autoantibodies, Methods of autoantibody detection, RNA polymerase III, Scl-70",
author = "Paulin, {John D.} and Neil McHugh",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-1-4419-5774-0_18",
language = "English",
isbn = "9781441957733",
pages = "209--225",
editor = "John Varga and Denton, {Christopher P.} and Wigley, {Fredrick M.}",
booktitle = "Scleroderma",
publisher = "Springer",

}

TY - CHAP

T1 - The clinical aspects of autoantibodies

AU - Paulin, John D.

AU - McHugh, Neil

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Disease classification in systemic sclerosis (SSc) is based primarily on the extent of skin involvement due to the recognition of its capacity to predict organ-specific manifestations. However, as shall be discussed in this chapter, antibody specificity, despite certain limitations, may prove of greater importance in predicting disease course and prognosis [1]. Circulating autoantibodies are attractive as biomarkers in SSc owing to their high specificity, the mutual exclusivity of the major SScautoantibody subtypes, their persistence for the duration of illness and most importantly, the characteristic constellation of clinical features associated with individual autoantibody groups [2, 3]. It is important to note, however, that the major clinical associations with SSc specific autoantibody reactivities, whilst of major prognostic value, are not absolute and organspecific manifestations can occur in the presence of any autoantibody reactivity [4].

AB - Disease classification in systemic sclerosis (SSc) is based primarily on the extent of skin involvement due to the recognition of its capacity to predict organ-specific manifestations. However, as shall be discussed in this chapter, antibody specificity, despite certain limitations, may prove of greater importance in predicting disease course and prognosis [1]. Circulating autoantibodies are attractive as biomarkers in SSc owing to their high specificity, the mutual exclusivity of the major SScautoantibody subtypes, their persistence for the duration of illness and most importantly, the characteristic constellation of clinical features associated with individual autoantibody groups [2, 3]. It is important to note, however, that the major clinical associations with SSc specific autoantibody reactivities, whilst of major prognostic value, are not absolute and organspecific manifestations can occur in the presence of any autoantibody reactivity [4].

KW - ANA

KW - Anticentromere

KW - Autoantibody types

KW - Clinical aspects of autoantibodies

KW - Methods of autoantibody detection

KW - RNA polymerase III

KW - Scl-70

UR - http://www.scopus.com/inward/record.url?scp=85022170489&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-5774-0_18

DO - 10.1007/978-1-4419-5774-0_18

M3 - Chapter

SN - 9781441957733

SP - 209

EP - 225

BT - Scleroderma

A2 - Varga, John

A2 - Denton, Christopher P.

A2 - Wigley, Fredrick M.

PB - Springer

CY - New York

ER -